NEUROLEPTIC MALIGNANT SYNDROME - A CASE REPORT by De souza, Joaquim Victor & Dias, Doreen
Indian Journal of Psychiatry, July 1986,28(3), pp. 259-260 
Brief Communications 
NEUROLEPTIC MALIGNANT SYNDROME - A CASE REPORT 
JOAQU1M VICTOR DE SOUZA
1 
DOREEN DIAS
2 
Introduction 
Neuroleptic malignant syndrome is re-
cognised as a rare and idiosyncratic side ef-
fect ot almost all antipsychotic drugs (Vin-
ken and Bruyn 1968). This disorder re-
ceives little or no attention in most of the 
psychiatric and psychopharmacologic text 
books. Long acting phenothiazines as well 
as other neuroleptics have been incri-
minated the most, but other drugs such as 
Tiaprides, MAO-I, Tricyclic combinations, 
Lithium-neuroleptic combinations have 
also been known to cause this catatonic 
syndrome. It is described that organic brain 
disease, exhaustion and dehydration may be 
additional factors (Itoh, Ohtsuka & Ogita 
1977, Mett/er 1973). Even short duration 
ot exposure to neuroleptics can bring about 
the syndrome which is characterised by ge-
neralised ngidity, akinesia and mutism, hy-
perpyrexia, autonomic dysfunction and 
tluctuating levels ot consciousness. Among 
the sixty cases in literature, 20 per cent 
mortality rate has been reported by Caroff 
(1980), usually due to cardiovascular col-
lapse, cardiac arrhythmias, renal or respira-
tory failure (Morrant 1984). 
We present a case report of a patient 
who had received Haloperidol 300 mg. and 
Chlorpromazine 1000 mg over 10 days in 
the past for control of symptoms of mania, 
but who developed neuroleptic malignant 
syndrome within 72 hours of hospitaliza-
tion and administration of these drugs. 
Case Report 
Mrs. 'A', a 45 year old female, whose 
diagnosis according to DSM III criteria was 
Affective Disorder, Bipolar, Manic type, 
was hospitalised for symptoms of marked 
aggressiveness, abusiveness, overtalkativen-
css and sleeplessness. During the next 3 
days she received a total of 60 mg. Paren-
teral Haloperidol (I. M.) and Chlorpromaz-
ine 300 mg. in divided doses. Three days af-
ter the initiation of haloperidol and Chlor-
promazine she was noted to be mute with 
marked generalised rigidity and akinesia. 
Her pulse, B. P., and temperature were nor-
mal. At that time we felt she was having E. 
P. S., so all neuroleptic medication was 
stopped and she received only antiparkin-
sonian agents, but the akinesia and rigidity 
worsened. Soon, she developed pyrexia 
(105°F), profuse diaphoresis, urinary incon-
tinence and refused to take oral feeds. 
There was clouding of her sensorium but 
she would respond only to painful stimuli. 
The B. P. recorded was 160/116 mm. Hg., 
Pulse 140/mt., and tachypnoea was present. 
In addition to the generalised hypcrtonus 
she also had marked tremors. No pyramidal 
signs were detected. The fundus examina-
tion, apart from arteriosclerotic changes Gr. 
II, was grossly normal. 
There were no significant laboratory 
finding. Blood counts, chest X ray, kidney 
function test, blood glucose and serum elec-
trolytes did not show any abnormalities. 
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Apart from increased heart rate, the ECG 
was within normal limits. 
The consulting Physician opined ence-
phalitis and later septicaemic shock, even 
though, at this stage, a doubt of NMS was 
kept in mind. Parenteral antibiotics, I. V. 
fluids, and steroids were started. 
However, her general condition conti-
nued to deteriorate over the next 24 hours. 
Her body temperature varied from 102°-
106T., never touching baseline. There 
were wide fluctuations of her B. P., lowest 
recording being 50 mm. Hg.,systolic (dias-
tolic not recordable). Her pupils were 
dilated and sluggishly reacting to light, and 
she was not responding to even painful 
stimuli. Her respiration became stertorous 
and she died on the 5th day of becoming 
mute and rigid. 
Blood and urine cultures which were 
sent at the time of admission were reported 
sterile. Post mortem C. S. F. examination 
did not reveal any pathological findings. 
Discussion 
Mrs. 'A', whose past history revealed 
several episodes of mania, developed NMS 
after the administration of chlorpromazine 
and haloperidol. The diagnosis of NMS was 
made after excluding all organic diseases 
that can cause catatonic stupor as described 
by Gelenberg (1976), such as encephalitis, 
meningitis, malignant hyperthermia, etc. 
The patient had shown a good response to 
the same drugs in the past attacks. This idio-
syncratic reaction with such a combination 
has not been commonly reported. In fact, 
most of the reports have primarily implicat-
ed long acting fluphenazine derivatives as 
the causative agents (Caroff 1980). The 
patient developed classical symptoms as 
described in the literature. Delay and De-
niker (1968) suggest that respiratory in-
sufficiency is- a cardinal feature of NMS as 
observed in this patient who also had 
marked dyspnoea not secondary to any lung 
pathology although Caroff (1980) re-
marked that the dyspnoea observed in the 
16 cases reported in the literature was the 
result of pneumonia or pulmonary emboli 
following prolonged immobilisation. The 
development of the symptoms had been ra-
ther explosive leading to death due to'car-
dio respiratory failure, although it has been 
reported that NMS lasts 5-10 days after ces-
sation of oral neuroleptics. 
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